Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
JCO Oncology Advances|May 7, 2025
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage ActivationGulam A Manji, Liam J Stanton, Angela C Hirbe, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Nature Genetics|October 28, 2025
Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinomaMorteza Chalabi Hajkarim, Michael May, Amit Dipak Amin, et al.
Nature Medicine|March 30, 2026
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trialZev A Wainberg, Gulam A Manji, Nathan Bahary, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancerH Carlo Maurer, Alvaro Garcia-Curiel, Sam R Holmstrom, et al.
Oncoimmunology|May 13, 2022
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinomaRobyn D Gartrell, Thomas Enzler, Pan S Kim, et al.
JCO Precision Oncology|June 12, 2026
Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTOBrian W Labadie, Aleksandar Obradovic, Alexander G Raufi, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
Pageof 5